Undervalued Health care stocks, tonight
Drugs, devices, hospitals, and insurers. Skip if you do not follow biotech.
Prices from Monday’s close (5 October).
Start with a ready-made list
- Safe and steadyStrong businesses with little debt and no serious warning signs.9 companiesShowing now
- Cheap, and insiders are buyingBosses bought shares with their own money in the last 90 days.5 companies
- Owned by famous fundsAt least two of the funds we track hold it.48 companies
- Bargains near their 1-year lowStrong enough for our list and close to a 1-year low.6 companies
- Paid to waitPays a dividend of 2% or more, with low debt.1 company
Size
Index
SignalsClear
Picks
- Near its 1-year low. The price is within 10% of its lowest point in the past year.
- Low debt. Owes less than half of what the business is worth on its books. Banks and insurers are left out.
- Growing steadily. Sales grew at least 5% a year for five years, with spare cash every year.
- Best businesses only. Only the companies that score 85 or more out of 100 on quality.
Pays you cash each year. 4% means $4 a year for every $100 of shares.
WarningsKeeps companies we fully checked that show none of these serious signs: doubt it can keep going, weak checks on its own accounts, or a notice that its past accounts can't be relied on. One big customer or a new auditor doesn't remove a company: those are only worth knowing. We don't check lawsuits, investigations or debt yet.
Hide companies with…
We read each company's latest annual report and recent SEC notices for these five signs only.
9 companies match
| Company | What they do | Price | Market value | Cash yield | Price to profit | Return on capital | Funds | Score | Compare | |
|---|---|---|---|---|---|---|---|---|---|---|
| InnovivaINVA | Innoviva sells hospital drugs to hospitals and earns royalties from GSK. | $20.6425% above 1-year low | $1.5bn | 12.7% | 7.3× | 15.8% | 5 | 1.01 | See why | |
| Harmony Biosciences HoldingsHRMY | Harmony Biosciences sells narcolepsy medicine to patients with sleep disorders. | $39.9256% above 1-year low | $2.3bn | 15.0% | 8.4× | 43.5% | 6 | 1.00 | See why | |
| Boston ScientificBSXCluster buy | Boston Scientific sells medical devices to hospitals, doctors, and healthcare providers. | $42.40at 1-year low | $61.4bn | 5.9% | 17.7× | 6.4% | 11 | 1.00 | See why | |
| Regeneron PharmaceuticalsREGN | Regeneron Pharmaceuticals sells prescription medicines to patients and doctors. | $726.4734% above 1-year low | $78.9bn | 4.8% | 20.6× | 12.3% | 10 | 0.93 | See why | |
| ResmedRMD | ResMed sells sleep apnea devices, ventilators, masks, and software to patients, clinics, and hospitals. | $222.8624% above 1-year low | $32.1bn | 5.1% | 16.6× | 20.5% | 3 | 0.84 | See why | |
| Viemed HealthcareVMD | Viemed sells home medical equipment and in-home care to patients in the United States. | $9.2453% above 1-year low | $352m | 8.3% | 15.3× | 12.0% | 1 | 0.72 | See why | |
| Cooper CompaniesCOOCluster buy | Cooper sells contact lenses and surgical products to eye care and women’s health providers. | $56.7711% above 1-year low | $10.8bn | 6.3% | 24.2× | 4.8% | 15 | 0.70 | See why | |
| SterisSTE | STERIS sells infection-prevention products and services to healthcare and life science customers. | $211.078% above 1-year low | $20.6bn | 4.5% | 19.3× | 7.1% | 10 | 0.62 | See why | |
| U S Physical TherapyUSPH | U S Physical Therapy sells physical therapy and injury prevention services to patients and employers. | $83.9644% above 1-year low | $1.3bn | 5.1% | 18.9× | 9.6% | 1 | 0.55 | See why |